Physician profile
Akeela Dossa
NPI 1396222121
$7,320.99
in general payments reported to CMS, 2019-2025
27 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $847 · 2022: $2,377 · 2023: $1,764 · 2024: $1,129 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,096.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $817.87 | 2021-2024 | Spravato |
| Abbvie INC. | $760.37 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $756.29 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $734.39 | 2022-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $658.18 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $508.14 | 2022-2025 | Lybalvi |
| Astrazeneca Pharmaceuticals LP | $349.90 | 2021-2022 | |
| Corium, LLC | $244.25 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $225.40 | 2023-2024 | Auvelity |
| Neos Therapeutics, LP | $217.24 | 2022-2023 | Adzenys Xr-Odt |
| Horizon Therapeutics Plc | $198.59 | 2022-2023 | Krystexxa |
| Impel Pharmaceuticals INC. | $196.57 | 2022-2023 | Trudhesa |
| Boston Scientific Corporation | $193.07 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $148.21 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $142.58 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $135.99 | 2023 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $131.18 | 2025 | Cobenfy |
| Astellas Pharma US INC | $128.93 | 2025 | Veozah |
| Alpha Cognition USA, INC. | $124.89 | 2025 | Zunveyl |
| Gilead Sciences, INC. | $121.74 | 2025 | Descovy |
| Kowa Pharmaceuticals America, INC. | $119.86 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $111.90 | 2021 | |
| Novo Nordisk INC | $108.21 | 2022 | |
| Almatica Pharma LLC | $80.70 | 2022 | |
| Scynexis, INC. | $78.86 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.65 | 2023 | Quviviq |
| Lundbeck LLC | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akeela Dossa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.